ACTG Publications

TitleAuthorsDateJournalIssueVolume
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.Cillo, Anthony R ; Hilldorfer, Benedict B ; Lalama, Christina M ; McKinnon, John E ; Coombs, Robert W ; Tenorio, Allan R ; Fox, Lawrence ; Gandhi, Rajesh T ; Ribaudo, Heather ; Currier, Judith S ; Gulick, Roy M ; Wilkin, Timothy J ; Mellors, John W2015 Oct 23AIDS1629
Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.Tsibris, Athe M N ; Hu, Zixin ; Paredes, Roger ; Leopold, Kay E ; Putcharoen, Opass ; Schure, Allison L ; Mazur, Natalie ; Coakley, Eoin ; Su, Zhaohui ; Gulick, Roy M ; Kuritzkes, Daniel R2012 JunJ Virol1286
Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.Yeh, Tzu-min ; Evans, Scott R ; Gulick, Roy M ; Clifford, David B2010 Jan-FebHIV Clin Trials111
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.Grady, Benjamin J ; Torstenson, Eric S ; McLaren, Paul J ; DE Bakker, Paul I W ; Haas, David W ; Robbins, Gregory K ; Gulick, Roy M ; Haubrich, Richard ; Ribaudo, Heather ; Ritchie, Marylyn D2011Pac Symp Biocomput
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.Wilkin, Timothy J ; Su, Zhaohui ; Krambrink, Amy ; Long, Jianmin ; Greaves, Wayne ; Gross, Robert ; Hughes, Michael D ; Flexner, Charles ; Skolnik, Paul R ; Coakley, Eoin ; Godfrey, Catherine ; Hirsch, Martin ; Kuritzkes, Daniel R ; Gulick, Roy M2010 AugJ Acquir Immune Defic Syndr554
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.Gulick, Roy M ; Ribaudo, Heather J ; Shikuma, Cecilia M ; Lalama, Christina ; Schackman, Bruce R ; Meyer, William A ; Acosta, Edward P ; Schouten, Jeffrey ; Squires, Kathleen E ; Pilcher, Christopher D ; Murphy, Robert L ; Koletar, Susan L ; Carlson, Margrit ; Reichman, Richard C ; Bastow, Barbara ; Klingman, Karin L ; Kuritzkes, Daniel R 2006 Aug 16JAMA7296
Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.Schouten, Jeffrey T ; Krambrink, Amy ; Ribaudo, Heather J ; Kmack, Anne ; Webb, Nancy ; Shikuma, Cecilia ; Kuritzkes, Daniel R ; Gulick, Roy M2010 Mar 1Clin Infect Dis550
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.Gulick, Roy M ; Wilkin, Timothy J ; Chen, Ying Q ; Landovitz, Raphael J ; Amico, K Rivet ; Young, Alicia M ; Richardson, Paul ; Marzinke, Mark A ; Hendrix, Craig W ; Eshleman, Susan H ; McGowan, Ian ; Cottle, Leslie M ; Andrade, Adriana ; Marcus, Cheryl ; Klingman, Karin L ; Chege, Wairimu ; Rinehart, Alex R ; Rooney, James F ; Andrew, Phi2017 Sep 19Ann Intern Med6167
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.Su, Zhaohui ; Gulick, Roy M ; Krambrink, Amy ; Coakley, Eoin ; Hughes, Michael D ; Han, Dong ; Flexner, Charles ; Wilkin, Timothy J ; Skolnik, Paul R ; Greaves, Wayne L ; Kuritzkes, Daniel R ; Reeves, Jacqueline D ; AIDS Clinical Trials Group A5211 Team2009 Dec 1J Infect Dis11200
The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients.Wilkin, Timothy J ; Ribaudo, Heather R ; Tenorio, Allan R ; Gulick, Roy M2010 Nov-DecHIV Clin Trials611
Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.Weinberg, Adriana ; Bosch, Ronald ; Bennett, Kara ; Tovar-Salazar, Adriana ; Benson, Constance A ; Collier, Ann C ; Zolopa, Andrew ; Gulick, Roy M ; Wohl, David ; Polsky, Bruce ; Erice, Alejo ; Jacobson, Mark A2014 May 1J Acquir Immune Defic Syndr166
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.Wilkin, Timothy J ; Goetz, Mathew Bidwell ; Leduc, Robert ; Skowron, Gail ; Su, Zhaohui ; Chan, Ellen S ; Heera, Jayyant ; Chapman, Doug ; Spritzler, John ; Reeves, Jacqueline D ; Gulick, Roy M ; Coakley, Eoin2011 Apr 1Clin Infect Dis752
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.Benson, Constance A ; Vaida, Florin ; Havlir, Diane V ; Downey, Gerald F ; Lederman, Michael M ; Gulick, Roy M ; Glesby, Marshall J ; Wantman, Michael ; Bixby, Christian J ; Rinehart, Alex R ; Snyder, Sally ; Wang, Rui ; Patel, Sheran ; Mellors, John W ; ACTG A5086 Study Team2006 Nov 1J Infect Dis9194
Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.Schackman, Bruce R ; Ribaudo, Heather J ; Krambrink, Amy ; Hughes, Valery ; Kuritzkes, Daniel R ; Gulick, Roy M2007 Dec 15J Acquir Immune Defic Syndr546
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.Ribaudo, Heather J ; Smith, Kimberly Y ; Robbins, Gregory K ; Flexner, Charles ; Haubrich, Richard ; Chen, Yun ; Fischl, Margaret A ; Schackman, Bruce R ; Riddler, Sharon A ; Gulick, Roy M2013 DecClin Infect Dis1157
Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.Mollan, Katie R ; Tierney, Camlin ; Hellwege, Jacklyn N ; Eron, Joseph J ; Hudgens, Michael G ; Gulick, Roy M ; Haubrich, Richard ; Sax, Paul E ; Campbell, Thomas B ; Daar, Eric S ; Robertson, Kevin R ; Ventura, Diana ; Ma, Qing ; Edwards, Digna R Velez ; Haas, David W ; AIDS Clinical Trials Group2017 Sep 01J Infect Dis5216
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.Tsibris, Athe M N ; Korber, Bette ; Arnaout, Ramy ; Russ, Carsten ; Lo, Chien-Chi ; Leitner, Thomas ; Gaschen, Brian ; Theiler, James ; Paredes, Roger ; Su, Zhaohui ; Hughes, Michael D ; Gulick, Roy M ; Greaves, Wayne ; Coakley, Eoin ; Flexner, Charles ; Nusbaum, Chad ; Kuritzkes, Daniel R2009PLoS One54
Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects.Gupta, Samir K ; Komarow, Lauren ; Gulick, Roy M ; Pollard, Richard B ; Robbins, Gregory K ; Franceschini, Nora ; Szczech, Lynda A ; Koletar, Susan L ; Kalayjian, Robert C2009 Aug 15J Infect Dis4200
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.Kuritzkes, Daniel R ; Lalama, Christina M ; Ribaudo, Heather J ; Marcial, Michelle ; Meyer, William A ; Shikuma, Cecilia ; Johnson, Victoria A ; Fiscus, Susan A ; D'Aquila, Richard T ; Schackman, Bruce R ; Acosta, Edward P ; Gulick, Roy M2008 Mar 15J Infect Dis6197
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.Paredes, Roger ; Lalama, Christina M ; Ribaudo, Heather J ; Schackman, Bruce R ; Shikuma, Cecilia ; Giguel, Francoise ; Meyer, William A ; Johnson, Victoria A ; Fiscus, Susan A ; D'Aquila, Richard T ; Gulick, Roy M ; Kuritzkes, Daniel R ; AIDS Clinical Trials Group (ACTG) A5095 Study Team2010 MarJ Infect Dis5201
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.Kuritzkes, Daniel R ; Ribaudo, Heather J ; Squires, Kathleen E ; Koletar, Susan L ; Santana, Jorge ; Riddler, Sharon A ; Reichman, Richard ; Shikuma, Cecilia ; Meyer, William A ; Klingman, Karin L ; Gulick, Roy M ; ACTG A5166s Protocol Team2007 Apr 15J Infect Dis8195
Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.Moore, Carrie B ; Verma, Anurag ; Pendergrass, Sarah ; Verma, Shefali S ; Johnson, Daniel H ; Daar, Eric S ; Gulick, Roy M ; Haubrich, Richard ; Robbins, Gregory K ; Ritchie, Marylyn D ; Haas, David W2015 JanOpen Forum Infect Dis12
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).Gulick, Roy M ; Wilkin, Timothy J ; Chen, Ying Q ; Landovitz, Raphael J ; Amico, K Rivet ; Young, Alicia M ; Richardson, Paul ; Marzinke, Mark A ; Hendrix, Craig W ; Eshleman, Susan H ; McGowan, Ian ; Cottle, Leslie M ; Andrade, Adriana ; Marcus, Cheryl ; Klingman, Karin L ; Chege, Wairimu ; Rinehart, Alex R ; Rooney, James F ; Andrew, Phi2017 Jan 15J Infect Dis2215
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.Gulick, Roy M ; Su, Zhaohui ; Flexner, Charles ; Hughes, Michael D ; Skolnik, Paul R ; Wilkin, Timothy J ; Gross, Robert ; Krambrink, Amy ; Coakley, Eoin ; Greaves, Wayne L ; Zolopa, Andrew ; Reichman, Richard ; Godfrey, Catherine ; Hirsch, Martin ; Kuritzkes, Daniel R ; AIDS Clinical Trials Group 5211 Team2007 Jul 15J Infect Dis2196
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.Ribaudo, Heather J ; Haas, David W ; Tierney, Camlin ; Kim, Richard B ; Wilkinson, Grant R ; Gulick, Roy M ; Clifford, David B ; Marzolini, Catia ; Fletcher, Courtney V ; Tashima, Karen T ; Kuritzkes, Daniel R ; Acosta, Edward P ; Adult AIDS Clinical Trials Group Study2006 Feb 1Clin Infect Dis342
Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.Haubrich, Richard H ; Jiang, Hongyu ; Swanstrom, Ronald ; Bates, Michael ; Katzenstein, David ; Petch, Leslie ; Fletcher, Courtney V ; Fiscus, Susan A ; Gulick, Roy M ; AIDS Clinical Trials Group Protocol 359 Team2007 Mar-AprHIV Clin Trials28
No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305.Kapadia, Shashi N ; Wu, Chunyuan ; Mayer, Kenneth H ; Wilkin, Timothy J ; Amico, K Rivet ; Landovitz, Raphael J ; Andrade, Adriana ; Chen, Ying Q ; Chege, Wairimu ; McCauley, Marybeth ; Gulick, Roy M ; Schackman, Bruce R2018PLoS One1213
Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times.Johnson, Brent A ; Ribaudo, Heather ; Gulick, Roy M ; Eron, Joseph J2013 SepBiometrics369
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).Shikuma, Cecilia M ; Yang, Yang ; Glesby, Marshall J ; Meyer, William A ; Tashima, Karen T ; Ribaudo, Heather J ; Webb, Nancy ; Bastow, Barbara ; Kuritzkes, Daniel R ; Gulick, Roy M2007 Apr 15J Acquir Immune Defic Syndr544
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV.Schacker, Timothy W ; Bosch, Ronald J ; Bennett, Kara ; Pollard, Richard ; Robbins, Gregory K ; Collier, Ann C ; Gulick, Roy M ; Spritzler, John ; Mildvan, Donna ; AIDS Clinical Trials Group2010 May 1J Acquir Immune Defic Syndr154
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.International HIV Controllers Study ; Pereyra, Florencia ; Jia, Xiaoming ; McLaren, Paul J ; Telenti, Amalio ; DE Bakker, Paul I W ; Walker, Bruce D ; Ripke, Stephan ; Brumme, Chanson J ; Pulit, Sara L ; Carrington, Mary ; Kadie, Carl M ; Carlson, Jonathan M ; Heckerman, David ; Graham, Robert R ; Plenge, Robert M ; Deeks, Steven G ; Giann2010 Dec 10Science6010330
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.Tsibris, Athe M N ; Paredes, Roger ; Chadburn, Amy ; Su, Zhaohui ; Henrich, Timothy J ; Krambrink, Amy ; Hughes, Michael D ; Aberg, Judith A ; Currier, Judith S ; Tashima, Karen ; Godfrey, Catherine ; Greaves, Wayne ; Flexner, Charles ; Skolnik, Paul R ; Wilkin, Timothy J ; Gulick, Roy M ; Kuritzkes, Daniel R2009 Mar 1Clin Infect Dis548
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).Clifford, David B ; Evans, Scott ; Yang, Yijun ; Acosta, Edward P ; Ribaudo, Heather ; Gulick, Roy M ; A5097s Study Team2009 Nov-DecHIV Clin Trials610
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.Gulick, Roy M ; Lalama, Christina M ; Ribaudo, Heather J ; Shikuma, Cecilia M ; Schackman, Bruce R ; Schouten, Jeffrey ; Squires, Kathleen E ; Koletar, Susan L ; Pilcher, Christopher D ; Reichman, Richard C ; Klingman, Karin L ; Kuritzkes, Daniel R2007 Apr 23AIDS721
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.Tsibris, Athe M N ; Sagar, Manish ; Gulick, Roy M ; Su, Zhaohui ; Hughes, Michael ; Greaves, Wayne ; Subramanian, Mani ; Flexner, Charles ; Giguel, Francoise ; Leopold, Kay E ; Coakley, Eoin ; Kuritzkes, Daniel R2008 AugJ Virol1682
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.Putcharoen, Opass ; Lee, Sun Hee ; Henrich, Timothy J ; Hu, Zixin ; Vanichanan, Jakapat ; Coakley, Eoin ; Greaves, Wayne ; Gulick, Roy M ; Kuritzkes, Daniel R ; Tsibris, Athe M N2012 JanJ Virol286
Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.Anderson, Jeffrey A ; Jiang, Hongyu ; Ding, Xiao ; Petch, Leslie ; Journigan, Terri ; Fiscus, Susan A ; Haubrich, Richard ; Katzenstein, David ; Swanstrom, Ronald ; Gulick, Roy M ; AIDS Clinical Trials Group Study 359 Protocol Team2008 MayAIDS Res Hum Retroviruses524
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Lehmann, David S ; Ribaudo, Heather J ; Daar, Eric S ; Gulick, Roy M ; Haubrich, Richard H ; Robbins, Gregory K ; DE Bakker, Paul I W ; Haas, David W ; McLaren, Paul J2015 FebPharmacogenet Genomics225
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.Holzinger, Emily R ; Grady, Benjamin ; Ritchie, Marylyn D ; Ribaudo, Heather J ; Acosta, Edward P ; Morse, Gene D ; Gulick, Roy M ; Robbins, Gregory K ; Clifford, David B ; Daar, Eric S ; McLaren, Paul ; Haas, David W2012 DecPharmacogenet Genomics1222
Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study.Henrich, Timothy J ; McLaren, Paul J ; Rao, Suhas S P ; Lin, Nina H ; Hanhauser, Emily ; Giguel, Francoise ; Gulick, Roy M ; Ribaudo, Heather ; DE Bakker, Paul I W ; Kuritzkes, Daniel R2014 MarOpen Forum Infect Dis11
Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.Figueroa, Dominique B ; Madeen, Erin P ; Tillotson, Joseph ; Richardson, Paul ; Cottle, Leslie ; McCauley, Marybeth ; Landovitz, Raphael J ; Andrade, Adriana ; Hendrix, Craig W ; Mayer, Kenneth H ; Wilkin, Timothy ; Gulick, Roy M ; Bumpus, Namandjé N2018 MayAIDS Res Hum Retroviruses534
Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095.Li, Li ; Eron, Joseph J ; Ribaudo, Heather ; Gulick, Roy M ; Johnson, Brent A2012J Am Stat Assoc498107
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.Ribaudo, Heather J ; Liu, Huan ; Schwab, Matthias ; Schaeffeler, Elke ; Eichelbaum, Michel ; Motsinger-Reif, Alison A ; Ritchie, Marylyn D ; Zanger, Ulrich M ; Acosta, Edward P ; Morse, Gene D ; Gulick, Roy M ; Robbins, Gregory K ; Clifford, David ; Haas, David W2010 Sep 1J Infect Dis5202
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.Ribaudo, Heather J ; Kuritzkes, Daniel R ; Lalama, Christina M ; Schouten, Jeffrey T ; Schackman, Bruce R ; Acosta, Edward P ; Gulick, Roy M2008 Apr 1J Infect Dis7197
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.Nyaku, Amesika N ; Zheng, Lu ; Gulick, Roy M ; Olefsky, Maxine ; Berzins, Baiba ; Wallis, Carole L ; Godfrey, Catherine ; Sax, Paul E ; Acosta, Edward P ; Haas, David W ; Smith, Kimberly Y ; Sha, Beverly E ; Van Dam, Cornelius N ; Taiwo, Babafemi O ; ACTG A5353 Study Team2019 Jan 18J Antimicrob Chemother
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.Henrich, Timothy J ; Lewine, Nicolas R P ; Lee, Sun-Hee ; Rao, Suhas S P ; Berro, Reem ; Gulick, Roy M ; Moore, John P ; Tsibris, Athe M N ; Kuritzkes, Daniel R2012 AprAntimicrob Agents Chemother456
Design issues in initial HIV-treatment trials: focus on ACTG A5095.Ribaudo, Heather J ; Kuritzkes, Daniel R ; Schackman, Bruce R ; Acosta, Edward P ; Shikuma, Cecilia M ; Gulick, Roy M2006Antivir Ther611
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.Morris, Bethany L ; Scott, Callie A ; Wilkin, Timothy J ; Sax, Paul E ; Gulick, Roy M ; Freedberg, Kenneth A ; Schackman, Bruce R2012 Jan-FebHIV Clin Trials113
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.Girouard, Michael P ; Sax, Paul E ; Parker, Robert A ; Taiwo, Babafemi ; Freedberg, Kenneth A ; Gulick, Roy M ; Weinstein, Milton C ; Paltiel, A David ; Walensky, Rochelle P2016 Mar 15Clin Infect Dis662
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.Namazi, Golnaz ; Fajnzylber, Jesse M ; Aga, Evgenia ; Bosch, Ronald J ; Acosta, Edward P ; Sharaf, Radwa ; Hartogensis, Wendy ; Jacobson, Jeffrey M ; Connick, Elizabeth ; Volberding, Paul ; Skiest, Daniel ; Margolis, David ; Sneller, Michael C ; Little, Susan J ; Gianella, Sara ; Smith, Davey M ; Kuritzkes, Daniel R ; Gulick, Roy M ; Mello2018 Nov 05J Infect Dis12218
A comparison of three initial antiretroviral AIDS regimens.Ribaudo, Heather J ; Kuritzkes, Daniel R ; Gulick, Roy M2007 Sep 6N Engl J Med10357
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.Mugavero, Michael J ; May, Margaret ; Ribaudo, Heather J ; Gulick, Roy M ; Riddler, Sharon A ; Haubrich, Richard ; Napravnik, Sonia ; Abgrall, Sophie ; Phillips, Andrew ; Harris, Ross ; Gill, M John ; de Wolf, Frank ; Hogg, Robert ; Günthard, Huldrych F ; Chêne, Geneviève ; D'Arminio Monforte, Antonella ; Guest, Jodie L ; Smith, Colette ; 2011 Nov 1J Acquir Immune Defic Syndr358
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.Shikuma, Cecilia M ; Ribaudo, Heather J ; Zheng, Yu ; Gulick, Roy M ; Meyer, William A ; Tashima, Karen T ; Bastow, Barbara ; Kuritzkes, Daniel R ; Glesby, Marshall J ; AIDS Clinical Trials Group A5095 Study Team2011 MayAIDS Res Hum Retroviruses527
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.Haas, David W ; Bradford, Yuki ; Verma, Anurag ; Verma, Shefali S ; Eron, Joseph J ; Gulick, Roy M ; Riddler, Sharon A ; Sax, Paul E ; Daar, Eric S ; Morse, Gene D ; Acosta, Edward P ; Ritchie, Marylyn D2018 JulPharmacogenet Genomics728
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.Mollan, Katie R ; Smurzynski, Marlene ; Eron, Joseph J ; Daar, Eric S ; Campbell, Thomas B ; Sax, Paul E ; Gulick, Roy M ; Na, Lumine ; O'Keefe, Lauren ; Robertson, Kevin R ; Tierney, Camlin2014 Jul 1Ann Intern Med1161
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.Hosoya, Noriaki ; Su, Zhaohui ; Wilkin, Timothy ; Gulick, Roy M ; Flexner, Charles ; Hughes, Michael D ; Skolnik, Paul R ; Giguel, Francoise ; Greaves, Wayne L ; Coakley, Eoin ; Kuritzkes, Daniel R2009 AugJ Clin Microbiol847
Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.Zheng, Yu ; Hughes, Michael D ; Lockman, Shahin ; Benson, Constance A ; Hosseinipour, Mina C ; Campbell, Thomas B ; Gulick, Roy M ; Daar, Eric S ; Sax, Paul E ; Riddler, Sharon A ; Haubrich, Richard ; Salata, Robert A ; Currier, Judith S2014 Sep 15Clin Infect Dis659
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.Taiwo, Babafemi O ; Zheng, Lu ; Stefanescu, Andrei ; Nyaku, Amesika ; Bezins, Baiba ; Wallis, Carole L ; Godfrey, Catherine ; Sax, Paul E ; Acosta, Edward ; Haas, David ; Smith, Kimberly Y ; Sha, Beverly ; Van Dam, Cornelius ; Gulick, Roy M2018 May 17Clin Infect Dis1166